Phase II, Multicenter, Randomized Trial of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus Intensive Salvage Therapy in Adults with First Relapse AML

BACKGROUND: CPX-351 is a liposome-encapsulated fixed-molar ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance anti-leukemic efficacy. METHODS: This Phase II study randomized 125 patients 2:1 to CPX-351 or investigator’s choice of first s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer
Main Authors: Cortes, Jorge E., Goldberg, Stuart L., Feldman, Eric J., Rizzeri, David A., Hogge, Donna E., Larson, Melissa, Pigneux, Arnaud, Recher, Christian, Schiller, Gary, Warzocha, Krzysztof, Kantarjian, Hagop, Louie, Arthur C., Kolitz, Jonathan E.
Format: Artigo
Jezik:Inglês
Izdano: 2014
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5542857/
https://ncbi.nlm.nih.gov/pubmed/25223583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28974
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki